Status:

COMPLETED

Dose-escalation Study of Single Dose GHB04L1 in Healthy Adults

Lead Sponsor:

AVIR Green Hills Biotechnology AG

Collaborating Sponsors:

Medical University of Vienna

Conditions:

Influenza

Eligibility:

MALE

18-50 years

Phase:

PHASE1

Brief Summary

It is the hypothesis of this study that intranasal vaccination with a single dose of GHB04L1 is safe and induces an immune response against influenza A H5N1. This hypothesis will be tested in a random...

Eligibility Criteria

Inclusion

  • Healthy male volunteers, 18-50 years
  • Seronegative for H5N1
  • Seronegative for H1N1 (with antibody titers ≤1:20)
  • Written informed consent to participate in this study

Exclusion

  • Acute febrile illness
  • Signs of acute or chronic upper or lower tract respiratory illnesses
  • History of severe atopy
  • Seasonal influenza vaccination from 2006/2007 onwards and/or pandemic influenza vaccination against H5N1
  • Known increased tendency of nose bleeding
  • Volunteers with clinically relevant abnormal paranasal anatomy
  • Volunteers with clinically relevant abnormal laboratory values
  • Simultaneous treatment with immunosuppressive drugs
  • Clinically relevant history of renal, hepatic, GI, cardiovascular,haematological, skin, endocrine, neurological or immunological diseases
  • History of leukaemia or cancer
  • HIV or Hepatitis B or C seropositivity
  • Volunteers who underwent rhino or sinus surgery, or surgery of another traumatic injury of the nose within 30 days prior to application of study medication
  • Volunteers who have received antiviral drugs, treatment with immunoglobulins or blood transfusions, or an investigational drug within four weeks prior to study medication application
  • Volunteers who have received anti-inflammatory drugs 2 days prior to study medication application
  • Volunteers who are not likely to cope with the requirements of the study or with a significant physical or mental condition that may interfere with the completion of the study

Key Trial Info

Start Date :

August 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2010

Estimated Enrollment :

32 Patients enrolled

Trial Details

Trial ID

NCT00741806

Start Date

August 1 2008

End Date

March 1 2010

Last Update

March 2 2010

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Dept of Clinical Pharmacology, Medical University Vienna

Vienna, Austria, 1090